What were Eli Lilly's Q1 2026 results?

The company did not disclose specific figures yet, but reported strong results and raised its annual guidance.

How did the obesity trial data affect Eli Lilly's stock?

Positive data for Foundayo and Zepbound helped the stock gain 9.13% over 30 days.

What is Eli Lilly's guidance for fiscal 2026?

The company raised its revenue and earnings guidance, but specific numbers have not been disclosed.

Did Eli Lilly expand its manufacturing plans?

Yes, the company announced expanded manufacturing plans to meet growing demand for obesity drugs.

What is Eli Lilly's year-to-date stock performance?

The stock is down 6.82% year-to-date, but has partially recovered with a 9.13% gain over the last 30 days.

Eli Lilly Raises Full-Year Guidance After Strong Q1, Obesity Trial Wins

Eli Lilly (LLY) reported strong Q1 results, raised its full-year revenue and earnings guidance, and released positive new obesity trial data for Foundayo and Zepbound. The stock gained 9.13% over 30 days, partially reversing a 6.82% year-to-date decline.

Eli Lilly (NYSE: LLY) reported strong financial results for the first quarter of 2026, driven by growth in obesity and diabetes drug sales. The company also raised its full-year revenue and earnings guidance and released positive new clinical trial data for its obesity drugs Foundayo and Zepbound. The news helped the stock recover some ground, posting a 9.13% return over the past 30 days after a year-to-date decline of 6.82%.

Key Financial Results

Metric	Q1 2026	YoY Change
Revenue	Not disclosed	-
Net Income	Not disclosed	-
EPS	Not disclosed	-

(Note: Specific financial figures were not provided in the original source.)

Highlights from the Announcement

Raised full-year 2026 revenue and earnings guidance.
Positive obesity trial data for Foundayo and Zepbound.
Expanded manufacturing plans to meet growing demand for obesity drugs.

Future Guidance

Eli Lilly raised its full-year 2026 revenue and earnings guidance, though specific numbers have not been disclosed.

Impact on the Stock

The stock gained 9.13% over 30 days, partially reversing a 6.82% year-to-date decline. This recovery reflects investor confidence in the company's growth prospects.

What This Means for Investors

The focus remains on Eli Lilly's ability to sustain growth momentum in the expanding obesity drug market, with clinical trial results and manufacturing expansion as key drivers. Investors should monitor upcoming financial reports for more detailed figures.